Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin-C in BRCA2-Mutated Pancreatic Cancer
NCT00386399Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: 6-month Overall Survival. Planned start Oct 2006; status: withdrawn.
02
Drugs
mitomycin c
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00386399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386399.